Análisis de la acción Nurix Therapeutics Inc (NRIX)NRIXNurix Therapeutics Inc

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nurix Therapeutics Inc is a good buy right now due to its recent collaboration with Roche, which has significantly bolstered its financial outlook with an upfront payment of $700 million and potential milestone payments up to $2.3 billion. The stock has shown a strong upward trend with a 1-year change of +111.52% and a current price of $25.34, which is below the average analyst price target of $33. This provides a solid upside potential of approximately 30% from the current price. However, the main risk is the company's recent net income loss of $87,174,000 in Q1 2026, which indicates ongoing financial challenges that investors should monitor closely.